Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Hartig Drug Company Inc. v. Senju Pharmaceutical Co. Ltd. et al
Case Number:
1:14-cv-00719
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
October 16, 2018
Firms Win $3M In Fees In Hartig Product-Hopping Suit
A Delaware federal judge on Monday awarded Frank LLP, Prickett Jones & Elliott PA and Hausfeld LLP $3 million in attorneys' fees in connection with Hartig Drug Co.'s suit settled earlier this year against Allergan Inc., Senju Pharmaceutical and Kyorin Pharmaceutical over claims the companies engaged in product-hopping for eye treatment products.
-
September 25, 2018
Hartig Seeks $3M In Attys' Fees In Product-Hopping Suit
The Hartig Drug Co. Inc. has asked a Delaware federal judge to award it $3 million in attorneys' fees in a suit against Allergan Inc., Senju Pharmaceutical Co. Ltd. and Kyorin Pharmaceutical Co. Ltd. alleging product-hopping over eye care products Zymar and Zymaxid.
-
February 16, 2018
Allergan, Others Cough Up $9M In Product-Hopping Suit
Allergan Inc., Senju Pharmaceutical Co. Ltd. and Kyorin Pharmaceutical Co. Ltd. have agreed to pay Hartig Drug Co. Inc. $9 million to end a putative class action alleging product-hopping over eye care products Zymar and Zymaxid, according to documents filed Friday in Delaware federal court.
-
August 20, 2015
Allergan Product-Hopping Suit Nixed On Faulty Assignments
A Delaware federal judge on Wednesday dismissed a product-hopping suit against Allergan Inc. over eye care products Zymar and Zymaxid after concluding the pharmacy chain that brought the putative class action did not have the right to sue as a direct purchaser under federal law.